1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. ATP Citrate Lyase

ATP Citrate Lyase

ACLY

ATP-citrate lyase (ACLY) is a central metabolic enzyme and catalyses the ATP-dependent conversion of citrate and coenzyme A (CoA) to oxaloacetate and acetyl-CoA. The acetyl-CoA product is crucial for the metabolism of fatty acids, the biosynthesis of cholesterol, and the acetylation and prenylation of proteins. Acetyl CoA is also required for acetylation reactions that modify proteins, such as histone acetylation. ACLY is upregulated or activated in several types of cancers, and its inhibition is known to induce proliferation arrest in cancer cells both in vitro and in vivo.

ACLY links glucose and lipid metabolism by catalyzing the formation of acetyl-CoA and oxaloacetate from citrate produced by glycolysis in the presence of ATP and CoA. ACLY is aberrantly expressed in many immortalized cells and tumors, such as breast, liver, colon, lung and prostate cancers, and is correlated reversely with tumor stage and differentiation, serving as a negative prognostic marker. ACLY is an upstream enzyme of the long chain fatty acid synthesis, providing acetyl-CoA as an essential component of the fatty acid synthesis. Therefore, ACLY is a key enzyme of cellular lipogenesis and potent target for cancer therapy.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-16450
    SB 204990
    Inhibitor 99.63%
    SB 204990 is a potent and specific inhibitor of ATP citrate lyase (ACLY) enzyme.
    SB 204990
  • HY-12357
    Bempedoic acid
    Inhibitor 98.99%
    Bempedoic acid (ETC-1002) is an ATP-citrate lyase (ACL) inhibitor. Bempedoic acid (ETC-1002) activates AMPK.
    Bempedoic acid
  • HY-16107
    BMS-303141
    Inhibitor 98.71%
    BMS-303141 is a potent, cell-permeable ATP-citrate lyase (ACL) inhibitor with an IC50 of 0.13 μM.
    BMS-303141
  • HY-127111
    NDI-091143
    Inhibitor 99.94%
    NDI-091143 is a potent and high-affinity human ATP-citrate lyase (ACLY) inhibitor with an IC50 of 2.1 nM (ADP-Glo assay), a Ki of 7.0 nM and a Kd of 2.2 nM. NDI-091143 inhibits ACLY catalysis allosterically, by stabilizing large conformational changes in the citrate domain that indirectly block the binding and recognition of citrate.
    NDI-091143
  • HY-W009156
    Citric acid tripotassium hydrate
    Inhibitor ≥99.0%
    Hydroxycitric acid tripotassium hydrate (Potassium citrate monohydrate) is the major active ingredient of Garcinia cambogia. Hydroxycitric acid tripotassium hydrate competitively inhibits ATP citrate lyase with weight loss benefits. Hydroxycitric acid tripotassium hydrate effective inhibits stones formation and also inhibits HIF, and has antioxidation, anti-inflammation and anti-tumor effects.
    Citric acid tripotassium hydrate
  • HY-16007
    (-)-Hydroxycitric acid
    Inhibitor 98.11%
    (-)-Hydroxycitric acid (Garcinia acid) is the principal acid of fruit rinds of Garcinia cambogia. (-)-Hydroxycitric acid is a potent and competitive and orally active inhibitor of ATP citrate lyase. (-)-Hydroxycitric acid suppresses the fatty acid synthesis, lipogenesis, food intake, and induced weight loss.
    (-)-Hydroxycitric acid
  • HY-W012946
    2-Furoic acid
    Inhibitor ≥98.0%
    2-Furoic acid (Furan-2-carboxylic acid) is an organic compound produced through furfural oxidation. 2-Furoic acid exhibits hypolipidemic effet, lowers both serum cholesterol and serum triglyceride levels in rats.
    2-Furoic acid
  • HY-P1123
    MEDICA16
    Inhibitor ≥98.0%
    MEDICA16, an ATP-citrate lyase inhibitor, significantly reduces intracellular TG content in gastrocnemius muscle, and this reduction is accompanied by an increase in insulin sensitivity. MEDICA16 is a selective agonist for GPR40 as well as selective partial agonists for GPR120.
    MEDICA16
  • HY-B1295
    Lithium citrate tetrahydrate
    Inhibitor ≥98.0%
    Lithium citrate (Litarex) tetrahydrate is the major active ingredient of Garcinia cambogia. Lithium citrate tetrahydrate competitively inhibits ATP citrate lyase with weight loss benefits. Lithium citrate tetrahydrate effective inhibits stones formation and also inhibits HIF, and has antioxidation, anti-inflammation and anti-tumor effects.
    Lithium citrate tetrahydrate
  • HY-N7347
    (-)-Hydroxycitric acid lactone
    Inhibitor
    (-)-Hydroxycitric acid lactone (Garcinia lactone) is an anti-obesity agent and a popular weight loss food supplement. (-)-Hydroxycitric acid lactone is a potent inhibitor of ATP-citrate lyase. (-)-Hydroxycitric acid lactone catalyzes the extramitochondrial cleavage of citrate to oxaloacetate and acetyl-CoA, limits the availability of acetyl-CoA units required for fatty acid synthesis.
    (-)-Hydroxycitric acid lactone
  • HY-12357S2
    Bempedoic acid-d4
    Inhibitor ≥98.0%
    Bempedoic acid-d4 is the deuterium labeled Bempedoic acid. Bempedoic acid (ETC-1002) is an ATP-citrate lyase (ACL) inhibitor. Bempedoic acid (ETC-1002) activates AMPK[1][2].
    Bempedoic acid-d<sub>4</sub>
  • HY-N11781
    Forrestiacids J
    Inhibitor
    Forrestiacids J is an ATP-citrate lyase (ACL) inhibitor with an IC50 of 2.6 μM.
    Forrestiacids J
  • HY-N11782
    Forrestiacids K
    Inhibitor
    Forrestiacids K, a terpenoid isolated from Pseudotsuga forrestii, acts as an ATP-citrate lyase (ACL) inhibitor.
    Forrestiacids K
  • HY-W012946S
    2-Furoic acid-d3
    2-Furoic acid-d3 is the deuterium labeled 2-Furoic acid[1]. 2-Furoic acid (Furan-2-carboxylic acid) is an organic compound produced through furfural oxidation[2]. 2-Furoic acid exhibits hypolipidemic effet, lowers both serum cholesterol and serum triglyceride levels in rats[3].
    2-Furoic acid-d<sub>3</sub>
  • HY-12357S
    Bempedoic acid-d5
    Bempedoic acid-d5 is the deuterium labeled Bempedoic acid[1]. Bempedoic acid (ETC-1002) is an ATP-citrate lyase (ACL) inhibitor[1]. Bempedoic acid (ETC-1002) activates AMPK[2].
    Bempedoic acid-d<sub>5</sub>
Cat. No. Product Name / Synonyms Application Reactivity